Skip to main content

Advertisement

SpringerLink
Log in

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose

Diabetes is present in patients with nonalcoholic fatty liver disease (NAFLD). The aim of this retrospective cohort study was to assess the cumulative development of type 2 diabetes and predictive factors for its development in Japanese patients with NAFLD.

Methods

A total of 6003 NAFLD patients diagnosed by ultrasonography were enrolled. The mean follow-up period was 4.9 years. An overnight (12 h) fasting blood sample or a casual blood sample was taken for routine analyses during follow up. The primary outcome was the development of type 2 diabetes. Evaluation was performed by using the Kaplan–Meier method and Cox proportional hazards analysis.

Results

Of the 6003 NAFLD patients, 411 patients developed type 2 diabetes. The cumulative development rate of type 2 diabetes was 6.8% at the 5th year and 17.7% at the 10th year. Multivariate Cox proportional hazards analysis showed that type 2 diabetes development in patients with NAFLD occurred when patients had prediabetes status (hazard ratio 6.39; 95% confidence interval 5.00–8.18; P < 0.001), mean serum gamma-glutamyltransferase (GGT) level of more than 109 IU/l (hazard ratio 1.60; 95% confidence interval 1.22–2. 02; P < 0.001), mean serum triglyceride (TG) level of more than 150 mg/l (hazard ratio 1.28; 95% confidence interval 1.05–1.55; P = 0.020), and physical activity of less than 60 min per week (hazard ratio 1.60; 95% confidence interval 1.25–2.00; P < 0.001).

Conclusions

The improvement of prediabetes status and physical activity, and the normalization of mean GGT and TG levels during follow up are important to prevent the development of T2DM in patients with NAFLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.

    Article  PubMed  CAS  Google Scholar 

  2. Williams R. Global changes in liver disease. Hepatology. 2006;44:521–6.

    Article  PubMed  Google Scholar 

  3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682–98.

    Article  PubMed  CAS  Google Scholar 

  4. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.

    Article  PubMed  Google Scholar 

  5. Fan JC, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50:204–10.

    Article  PubMed  Google Scholar 

  6. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509–18.

    Article  PubMed  CAS  Google Scholar 

  7. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.

    Article  PubMed  CAS  Google Scholar 

  8. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C. Stern MP identification of individuals with insulin resistance using routine clinical measurements. Diabetes. 2005;54:333–9.

    Article  PubMed  CAS  Google Scholar 

  9. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.

    Article  PubMed  CAS  Google Scholar 

  10. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39:909–14.

    Article  PubMed  Google Scholar 

  11. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E, et al. Chronic liver injury during obstructive sleep apnea. Hepatology. 2005;41:1290–6.

    Article  PubMed  Google Scholar 

  12. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest. 2008;133:92–9.

    Article  PubMed  CAS  Google Scholar 

  13. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086–91.

    Article  PubMed  CAS  Google Scholar 

  14. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a “bright” liver echopattern. Ital J Gastroenterol Hepatol. 1997;29:351–6.

    PubMed  CAS  Google Scholar 

  15. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.

    Article  PubMed  Google Scholar 

  16. Fleming TR, Harrington DP, O’Brien PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348–61.

    Article  PubMed  CAS  Google Scholar 

  17. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739–44.

    Article  PubMed  CAS  Google Scholar 

  18. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Man CD, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA. 2006;103:18273–7.

    Article  PubMed  CAS  Google Scholar 

  19. Perseghin G, Bonfanti R, Magni S, Lattuada G, De Cobelli F, Canu T, et al. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab. 2006;291:E697–703.

    Article  PubMed  CAS  Google Scholar 

  20. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology. 2007;46:716–22.

    Article  PubMed  CAS  Google Scholar 

  21. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449–57.

    Article  PubMed  Google Scholar 

  22. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  PubMed  CAS  Google Scholar 

  23. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.

    Article  PubMed  CAS  Google Scholar 

  24. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.

    Article  PubMed  Google Scholar 

  25. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, Isogawa A, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005;22:323–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The present work was supported in part by Grants-in-Aid from the Okinaka Memorial Institute for Medical Research and the Japanese Ministry of Health, Labour and Welfare. Moreover, the authors greatly acknowledge the editorial assistance of Thomas Hughes.

Conflict of interest statement

The authors declare that there is no conflict of interest associated with this study.

Author information

Authors and Affiliations

  1. Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan

    Yasuji Arase, Fumitaka Suzuki, Kenji Ikeda & Hiromitsu Kumada

  2. Department of Health Management, Toranomon Hospital, Tokyo, Japan

    Yasuji Arase & Hiroshi Tsuji

  3. Third Department of Internal Medicine (Metabolism), University of Yamanashi, Yamanashi, Japan

    Tetsuro Kobayashi

Authors
  1. Yasuji Arase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumitaka Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiromitsu Kumada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsuro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuji Arase.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arase, Y., Suzuki, F., Ikeda, K. et al. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 44, 1064–1070 (2009). https://doi.org/10.1007/s00535-009-0091-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-009-0091-1

Keywords

Search

Navigation